Memantine Merz (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist of the NMDA‑type glutamate receptor. By blocking excessive calcium influx through the receptor channel during pathological glutamate stimulation, it reduces excitotoxic neuronal damage while preserving normal synaptic transmission, which can slow cognitive decline in Alzheimer’s disease.

The dosing regimen for Memantine Merz is determined by the prescribing physician based on the patient’s clinical condition, renal function and tolerability. The prescriber will initiate and titrate the dose according to approved guidelines and individual response.

The safety of memantine during pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and use is generally avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant. Consultation with a healthcare professional is essential.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Memantine Merz. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA‑receptor antagonist class, whereas other approved agents such as donepezil, rivastigmine and galantamine are acetylcholinesterase inhibitors. Memantine is typically used in moderate to severe stages and may be combined with an acetylcholinesterase inhibitor for additive benefit, while the alternatives primarily target milder disease.

Memantine Merz should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the tablets in the original container, protect them from moisture, light and excessive heat, and keep them out of reach of children.

Memantine Merz is supplied as oral tablets that are taken by mouth with or without food. The tablets are swallowed whole and should be taken according to the schedule prescribed by the treating physician, usually once or twice daily after dose titration.

The most serious adverse events reported with memantine include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, seizures, anaphylactic allergic reactions and cardiac arrhythmias. Patients should seek immediate medical attention if any of these symptoms occur.

Memantine is contraindicated in patients with known hypersensitivity to memantine hydrochloride or any of the tablet excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA‑receptor antagonists, as these conditions may increase the risk of adverse effects.